Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA Expands Market Access, Authorizes New ENDS Products
  • Regulatory

FDA Expands Market Access, Authorizes New ENDS Products

FDA

FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.

Read full story

pharminent May 5, 2026 (Last updated: May 6, 2026)

FDA

FDA today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product application (PMTA) pathway.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Viridian data lift prospects for thyroid eye disease drug
Next: MSD concludes Terns acquisition to expand CML pipeline

Related Stories

  • Regulatory

Japan approves Sanofi’s Sarclisa combo for MM treatment

pharminent June 22, 2026
  • Regulatory

FDA experts endorse Moderna’s mRNA seasonal flu shot

pharminent June 19, 2026
  • Regulatory

Moderna flu vaccine wins unanimous support from FDA panel

pharminent June 18, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.